PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Clinical trial NCT05573893 · RECRUITING
Trial details
- NCT number
- NCT05573893
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2023-09-12
- Primary completion
- 2031-12-31
- Enrollment
- 800
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.